These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2804976)

  • 1. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
    Isaacs JT
    Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF; Heitjan DF; Lancaster S; Santen RJ
    Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.
    Isaacs JT; Coffey DS
    Cancer Res; 1981 Dec; 41(12 Pt 1):5070-5. PubMed ID: 7307008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
    Isaacs JT
    Cancer Res; 1982 Dec; 42(12):5010-4. PubMed ID: 6215981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
    Ellis WJ; Isaacs JT
    Cancer Res; 1985 Dec; 45(12 Pt 1):6041-50. PubMed ID: 4063963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
    Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
    Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
    Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
    Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
    Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
    Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death as a new target for prostatic cancer therapy.
    Kyprianou N; Martikainen P; Davis L; English HF; Isaacs JT
    Cancer Surv; 1991; 11():265-77. PubMed ID: 1841755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
    Humphries JE; Isaacs JT
    Cancer Res; 1982 Aug; 42(8):3148-56. PubMed ID: 7093958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
    Vukanovic J; Isaacs JT
    Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
    Smolev JK; Heston WD; Scott WW; Coffey DS
    Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.